AbbVie and Alvotech settle all US Humira litigation

AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

9 March 2023 The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.

Big Pharma

Humira: lessons from 20 years of patents, pricing and profits

21 March 2023 As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

Biotechnology

AbbVie wants USITC to investigate Alvotech over Humira ‘theft’

21 December 2021 AbbVie seeks to block imports of Alvotech’s biosimilar Humira into the US, claiming that the Icelandic company plundered former employees and used its trade secrets to develop the drug.

More on this story

Biotechnology

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

Big Pharma

Humira: lessons from 20 years of patents, pricing and profits

21 March 2023 As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

Biotechnology

AbbVie wants USITC to investigate Alvotech over Humira ‘theft’

More on this story

Biotechnology

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

Big Pharma

Humira: lessons from 20 years of patents, pricing and profits

21 March 2023 As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

Biotechnology

AbbVie wants USITC to investigate Alvotech over Humira ‘theft’